Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Surg Oncol
; 32: 2-7, 2020 Mar.
Article
in En
| MEDLINE
| ID: mdl-31670056
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Surg Oncol
Journal subject:
NEOPLASIAS
Year:
2020
Document type:
Article
Country of publication:
Países Bajos